FINWIRES · TerminalLIVE
FINWIRES

CPKC第一季度利润下降6.4%,低于预期,原因是营收下滑。

By

-- 加拿大太平洋铁路堪萨斯城分公司(CP.TO,CP)周三收盘后公布,由于营收下滑,第一季度调整后净利润同比下降6.4%,低于分析师预期。 截至3月31日的三个月,公司核心调整后净利润(不计大部分一次性项目)为9.29亿加元,合每股1.04加元,低于去年同期的9.92亿加元,合每股1.06加元。该业绩低于FactSet分析师一致预期的每股1.07加元。 该季度营收同比下降2.5%,从37.8亿加元降至37亿加元,同样低于FactSet预期的37.5亿加元。 铁路公司的核心运营比率(衡量效率的指标,数值越低越好)上升50个基点,从62.5%升至63%。 以收入吨英里衡量的货运量增长了2%,而核心调整后运营比率从62.5%上升50个基点至63.0%。 首席执行官基思·克里尔表示:“我们才华横溢的世界级铁路运输团队严格执行了精准的铁路运输计划,显著提升了网络流畅性、终端运营效率和其他关键运营指标,并取得了稳健的第一季度业绩。” 他补充道:“尽管市场和宏观经济持续面临不利因素,但我们依然实现了货运量增长,这充分展现了我们无与伦比的北美网络的韧性和竞争优势。” 此外,该公司周二宣布,董事会批准将季度股息提高17.5%,从每股22.8加分增至每股26.8加分。 该公司股票在纳斯达克盘后交易中下跌 1.18 美元,至 83.10 美元,此前在多伦多证券交易所收盘下跌 3.34 加元,至 115.30 加元。

Related Articles

Asia

Electro Optic Systems Reports Contract Backlog Growth as of March 31

Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.

$ASX:EOS
Asia

Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance

Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.

$ASX:REG
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.

$MDLZ